ACHV Q3 net loss $14.4M; FDA accepts cytisinicline NDA, PDUFA June 20, 2026

ACHIEVE LIFE SCIENCES, INC.

Net loss $14.4M for Q3 2025; cash, equivalents & marketable securities $48.1M at Sep 30.
FDA accepted cytisinicline NDA for smoking cessation; PDUFA target action date June 20, 2026.
FDA awarded Commissioner’s National Priority Voucher for vaping cessation, enabling 1-2 month expedited review.
Appointed Erik Atkisson as Chief Legal Officer; over 25 years biopharma legal experience.
New post hoc data in Thorax shows cytisinicline improved quit rates in adults with COPD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.